Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study

1. Chamorro-de-Vega, E.
2. Gimenez-Manzorro, A.
3. Rodriguez-Gonzalez, C.-G.
4. Escudero-Vilaplana, V.
5. De Lorenzo-Pinto, A.
6. Iglesias-Peinado, I.
7. Herranz-Alonso, A.
8. Sanjurjo Saez, M.